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Abstract
Most proteins in cell and tissue lysates are soluble. We show here
that in lysate from human neurons, more than 1,300 proteins are
maintained in a soluble and functional state by association with
endogenous RNA, as degradation of RNA invariably leads to protein
aggregation. The majority of these proteins lack conventional RNA-
binding domains. Using synthetic oligonucleotides, we identify the
importance of nucleic acid structure, with single-stranded
pyrimidine-rich bulges or loops surrounded by double-stranded
regions being particularly efficient in the maintenance of protein
solubility. These experiments also identify an apparent one-to-one
protein-nucleic acid stoichiometry. Furthermore, we show that
protein aggregates isolated from brain tissue from Amyotrophic
Lateral Sclerosis patients can be rendered soluble after refolding by
both RNA and synthetic oligonucleotides. Together, these findings
open new avenues for understanding themechanism behind protein
aggregation and shed light on how certain proteins remain soluble.
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Introduction
Under physiological conditions, the majority of cellular proteins
exist as soluble and folded entities. After protein synthesis, a
complex machinery of cellular chaperones facilitates correct
protein folding. Misfolded proteins are then identified and either
corrected or, if the correction has failed, removed through autop-
hagy or by the proteasome (Rubinsztein, 2006; Buchberger et al,
2010). Failure to resolve the misfolded state of proteins can lead
to pathological accumulation and deposition of insoluble protein
aggregates, as seen in many neurodegenerative diseases. However,
aggregation per se is not necessarily a pathological phenomenon
as various aspects of this process are also part of normal cellular
physiology (Kaganovich et al, 2008; David et al, 2010; Wallace
et al, 2015; Walther et al, 2015). For example, several proteins, in
particular RNA-binding proteins, are recruited into semi-soluble,
non-membrane encapsulated organelles such as stress granules
and p-bodies through the process of liquid–liquid phase separation
(Brangwynne, 2011). These, and similar structures, are not known
to form pathological aggregates as the individual components are
normally dynamically exchanged with the surrounding environ-
ment (Andersen et al, 2005; Kedersha et al, 2005; Spector &
Lamond, 2011; Decker & Parker, 2012). However, there are
several in vitro examples that liquid–liquid phase separation of
proteins can form stable aggregates reminiscent of structures
found in disease (Lin et al, 2015; Babinchak et al, 2019;
Narayanan et al, 2019; preprint: Ray et al, 2019). Some of the key
factors in liquid–liquid phase separations are just beginning to
emerge and include, for example, the presence of low-complexity
regions and/or unstructured regions in participating proteins (Kato
et al, 2012; Aguzzi & Altmeyer, 2016; Bergeron-Sandoval et al,
2016; Wu & Fuxreiter, 2016). RNA also appears to play an impor-
tant role in the formation of these structures. Indeed, RNA itself
undergoes phase transition (Jain & Vale, 2017) and has been
shown to promote phase transitions of several proteins (Lin et al,
2015; Molliex et al, 2015; Zhang et al, 2015), including Tau
(Zhang et al, 2017), and also to inhibit protein aggregation, most
notably of Fused in Sarcoma, FUS and TDP-43 (Shelkovnikova
et al, 2014; Burke et al, 2015; Mann et al, 2019). Recently, Maha-
rana et al (2018) showed that for several prion-like proteins,
including FUS, these disparate effects can be explained by the
ratio of protein to RNA, where excess of RNA promotes solubility
and decreased amount of RNA induces phase transition. Similar
results have also been observed for p53 and the prion protein
(Kovachev et al, 2017, 2019).
Most neurodegenerative diseases are associated with aggregation
of several proteins (Xia et al, 2008; Bai et al, 2013) and, curiously,
the same proteins are frequently found aggregated across multiple
diseases. For example, aggregated alpha-synuclein, a hallmark of
Parkinson’s disease, can also be found in Alzheimer’s disease
(Hamilton, 2000; Mandal et al, 2006), and aggregated TDP-43, a
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hallmark of Amyotrophic Lateral Sclerosis (ALS), can also be found
in both Alzheimer’s disease and Parkinson’s disease (Higashi et al,
2007; Nakashima-Yasuda et al, 2007). This indicates that a common
factor might control the soluble state of these proteins. Altered RNA
metabolism is a recurring theme in several neurodegenerative disor-
ders (e.g. Ramaswami et al, 2013; Conlon & Manley, 2017; Liu et al,
2017). In ALS and Frontotemporal Dementia, this is supported by
disease-causing genetic mutations in several RNA-binding proteins
as well as by the generation of potentially toxic RNA species (Sreed-
haran et al, 2008; Kwiatkowski et al, 2009; Vance et al, 2009; Fratta
et al, 2012; Kim et al, 2013; Haeusler et al, 2014). However, the link
between altered RNA metabolism and protein aggregation per se is
largely unexplored. Here, we show that RNA itself is critical in
maintaining solubility of several disease-associated and other aggre-
gation-prone proteins in cell and tissue lysates. These findings
expand on previous studies by indicating a more general role for
RNA, beyond its effect on RNA-binding proteins, in maintaining
solubility of certain proteins.
Results
Enzymatic degradation of RNA causes protein aggregation
Within a few minutes after adding RNase to a clear cell lysate, it
becomes opaque (Movie EV1), suggesting precipitation of material.
To investigate if the precipitate contained proteins, we treated
lysates prepared from human neurons and mouse brain cortex with
a mixture of RNase A and RNase T1 (A/T1) and identified any
aggregated proteins by gel electrophoresis (the experimental outline
is shown in Fig 1A). RNase treatment caused a concentration-
dependent aggregation of proteins from both samples (Figs 1A and
EV1A) and was accompanied by a decrease in both the amount and
size distribution of RNA in the lysate (Fig EV1B). RNase A/T1 treat-
ment for one hour at 37°C consistently precipitated 10%  1%
(n = 4) of the amount of input proteins from both human neurons
and mouse brain, a fraction that did not increase by prolonged
RNase treatment.
The specificity of the ribonuclease was not important for the
overall efficiency, as the single-stranded ribonucleases RNase A, T1
and 1f showed similar efficiency to the RNase A/T1 mixture
(Fig 1C). RNase V1, which is specific for double-stranded RNA, also
caused protein aggregation but only if EDTA was omitted from the
buffer and replaced with Mg2+, (Fig 1C). RNase V requires Mg2+
for its activity. However, DNase I failed to cause protein aggregation
in the presence of either EDTA or Mg2+ (Fig 1C). No proteins above
background (i.e. in samples without added nucleases) were aggre-
gated when increasing amounts of a ribonuclease inhibitor were
added to the lysate together with RNase A (Fig EV1C), or when
enzymatically or chemically (NaOH) degraded RNA was added to
the lysate (Fig EV1D).
Mass spectrometry identification of aggregated proteins
We used liquid chromatography tandem mass spectrometry (LC-
MS/MS) to identify the proteins which are aggregated by degrada-
tion of RNA in human neuronal cell lysates. More than 1,300 aggre-
gated proteins were found to be common to two biological
replicates (Dataset EV1). Gene ontology analysis of the data set
against a total proteome (approximately 6,600 proteins) from
human neurons (Song et al, 2019) using PANTHER indicates an
over-representation of protein-containing complexes (FDR
q = 1.22 × 1018), proteins involved in translation (FDR
q = 7.59 × 1012), RNA binding (FDR q = 1.97 × 1013) and hetero-
cyclic compound binding (FDR q = 5.93 × 1018; Fig EV2A–C and
Dataset EV1). Since mass spectrometry analysis of complex protein
mixtures is more likely to identify more abundant proteins than
proteins present in low quantities, we reanalysed our data set using
the proteins with higher than average relative abundance in Song
et al (2019) as background. Similar enrichment of GO terms was
A B C
Figure 1. Enzymatic degradation of RNA causes protein aggregation.
A Diagram showing the experimental design.
B SDS–PAGE analysis of soluble (Supernatant) and insoluble proteins (Pellet) from human neurons after treatment for one hour with a mixture of RNase A and RNase
T1 (A/T1), or vehicle (Ve-).
C Protein aggregation (Pellet) after incubation with different ribonucleases or DNase I in the presence of either EDTA or Mg2+. Ribonucleases used were RNase A (A),
RNase T1 (T1), a mixture of RNase A and RNase T1 (A/T1), RNase 1f (1f) and RNase V1 (V1).
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observed (Dataset EV1), suggesting that the proteins that aggregate
upon RNase treatment are not random. Recently, unstructured, low-
complexity regions in several RNA-binding proteins have been
shown to mediate protein phase transition (Kato et al, 2012).
However, both low-complexity (LC) and unstructured (US) regions
are significantly under-represented in our data set (Fig EV2D
and E).
The aggregated proteins include several proteins that are associ-
ated with neurodegenerative disease or other proteinopathies, such
as huntingtin (HTT), TDP-43, Gelsolin, Lysozyme, the heteroge-
neous nuclear ribonucleoproteins A2B1 (HNRNPA2B1), HNRNPA1,
and in one of the LC-MS/MS replicates, the valosin-containing
protein, VCP (Haltia et al, 1990; Pepys et al, 1993; DiFiglia et al,
1997; Hirabayashi et al, 2001; Watts et al, 2004; Neumann et al,
2006; Kimonis et al, 2008; Kim et al, 2013). We used Western blot
to validate the mass spectrometry data and to investigate the solu-
bility of other aggregation-prone proteins associated with proteino-
pathies. HTT, neurofilament heavy chain (NF-H), Tau (MAPT),
FUS, TDP-43, HNRNPA1, HNRNPD, RPL7 and actin (ACTB, found
aggregated in Hirano bodies in several neurodegenerative diseases;
Hirano, 1994), were selectively aggregated upon RNase A/T1 treat-
ment of human neuronal lysates (Fig 2A). However, the solubility
of poly A binding protein, PABP, an abundant RNA-binding
protein not identified in aggregates by mass spectrometry, was
unaffected by RNase treatment (Fig 2A). Similar results were
obtained using tissue lysate prepared from mouse cortex
(Fig EV3). We also detected an approximately 40 kDa Amyloid
beta (Ab)immunoreactive band in the pellet of RNase-treated
lysate (Fig 2A), possibly representing Ab oligomers (Walsh et al,
1997; McLean et al, 1999) formed from Ab generated in intracellu-
lar vesicles (Rajendran et al, 2006). Since the molecular weight of
this band is larger than expected, we also examined the aggrega-
tion of Ab in cell lysates prepared from HEK293T cells expressing
Ab fused to GFP. This fusion protein aggregated upon degradation
of RNA, while no aggregation was observed for GFP itself
(Fig 2B).
Inhibiting the added RNase activity with an RNase inhibitor abol-
ished the aggregation of HTT, NF-H and TDP-43 (Fig 2C).
RNA is required for maintaining the non-aggregated state of
renatured proteins
We next denatured proteins aggregated by enzymatic degradation
of RNA in 6M guanidine hydrochloride (GuHCl) and then
attempted to renature them in the presence or absence of total
RNA without any prior size fractionation (experimental outline
in Fig 3A). We hereafter refer to this process, i.e. GuHCl denatu-
ration of RNase-aggregated proteins followed by refolding in the
presence of various additives, as renaturation. After removal of
GuHCl, proteins remained soluble in the presence of RNA in an
RNA concentration-dependent manner, while the majority of
proteins without RNA re-aggregated (Fig 3B and C). Remarkably,
enzymatic degradation of RNA from the soluble fraction (Sup 1)
after renaturing in the presence of RNA caused the proteins to
re-aggregate (Fig 3C, Pel 2). The same principles were also
observed for individual proteins (Fig 3D).
Other nucleic acids, including total E. coli RNA and human
genomic DNA, efficiently prevented protein aggregation while
neither yeast tRNA nor heparin at the same amounts, did
(Fig EV4A). The effect of DNA is surprising since our data show that
proteins in cell lysate are maintained in a soluble state by intact
RNA and not by DNA (Fig 1C).
It is possible that the degradation of RNA causes the aggregation
of a few proteins that then co-sequester and aggregate with many
other proteins. To investigate this hypothesis, we therefore purified
recombinant TDP-43, which forms inclusion bodies in E. coli (Furu-
kawa et al, 2011; Capitini et al, 2014), under denaturing conditions
(6 M guanidine hydrochloride) and assessed the proportions of
soluble and insoluble TDP-43 when renatured in the presence or
absence of RNA. If co-sequestering did occur, then the presence or
absence of RNA should not affect the solubility of TDP-43. However,
we only obtained soluble TDP-43 when renatured with RNA
(Fig EV4B). Therefore, at least for TDP-43, the aggregation depends
solely on the availability of RNA, confirming previous studies that
TDP-43 aggregation is enhanced by lack of RNA interactions (Elden
et al, 2010; Pesiridis et al, 2011).
RNA is required for protein activity
Correct folding is required for the proper function of proteins. To
investigate whether the renatured proteins were functional and not
just solubilised, we assessed the ATP-hydrolysing activity of ATP-
binding proteins, which represent a large proportion of the aggre-
gated proteins (18%, 240/1312). As the ability to bind ATP depends
on the presence of conserved structural motifs (Walker et al, 1982),
we first investigated if the ability to bind ATP was restored in the
presence or absence of RNA. Proteins from human neurons bound
to ATP only in the presence of RNA (Fig EV4C), and LC-MS/MS
A B
C
Figure 2. Enzymatic degradation of RNA induces aggregation of proteins
associated with neurodegenerative diseases.
A, B Western blot analysis of soluble and aggregated proteins after RNase
treatment of lysate from human neurons (A), or HEK293T cells expressing
GFP-Ab or GFP (B).
C Effect of an RNase A inhibitor (RNasin) on RNase A mediated protein
aggregation in neuronal cell lysate.
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characterisation of these showed a clear enrichment of ATP-binding
proteins (58/143, Dataset EV2). RNA-renatured proteins hydrolysed
100-times more ATP than proteins without RNA (Fig 3E), and
concomitant degradation of RNA by the addition of RNase A/T1
hampered this activity (Fig 3E). Similar results were obtained with
aggregated proteins from Jurkat cells (Fig EV4D).
Identification of RNA sequences that are associated with
soluble proteins
To identify transcripts associated with soluble proteins in human
neuronal lysates, we performed native RNA immunoprecipitation
(RNA-IP) for Ab and NF-H, followed by sequencing. The majority of
associated transcripts were derived from protein-coding genes. 471
different transcripts associated with Ab and 123 with NF-H, respec-
tively (Dataset EV3). This RNA-IP experiment indicates which tran-
scripts are associated with the proteins in cell lysate but give little
information as to which regions, e.g. UTRs or coding regions, are
involved in the interactions. To increase the mapping resolution, we
therefore performed RNA immunoprecipitation for Ab and NF-H, as
well as Tau, on proteins renatured with pre-fragmented total Jurkat
RNA (~100 nucleotides).
For all three proteins, binding peaks were mainly observed in
exons (33–53% of all binding sites), in introns (15–21%) and in 30-
UTRs (6–10%), respectively (Fig 4A, GEO GSE99127). As in the
native RNA-IP experiments on Ab and NF-H, the vast majority of
the binding sites derived from exons and introns came from protein-
coding transcripts (Fig 4A). Between a fifth (NF-H 25/123) and a
third (Ab 180/471) of all coding transcripts in the native RNA-IP
experiments for A and NF-H were also represented by binding peaks
in the renatured samples (Dataset EV3). These experiments indicate
that soluble Ab, NF-H and Tau are associated with a variety of tran-
scripts, particularly with the coding regions of these. To further
deduce the principles governing this phenomenon, we next turned
to DNA, which, because of the similar renaturation capacity to RNA
(Fig EV4A), represents a convenient and easily manipulated model
system.
First, to identify DNA sequences capable of renaturing aggre-
gated proteins, we performed two sets of isolation and sequencing




Figure 3. RNA is required for renaturation and function of proteins aggregated by enzymatic degradation of RNA in human neuronal lysates.
A Diagram showing the renaturing assay.
B Effect of RNA/protein ratio on protein aggregation after renaturing.
C Coomassie-stained gel of soluble (Sup 1/2) and aggregated (Pel 1/2) proteins after removal of GuHCl in the presence (+) or absence () of total RNA. Asterisk (*)
denotes added RNase A.
D As in (C) but analysed by Western blot.
E ATP-hydrolysing activity of proteins renatured with total RNA or buffer (Ve) after removal of GuHCl.
Data information: All experiments were performed with total RNA. Data in (B and E) are expressed in arbitrary units (AU) and represent the mean  s.d of two (B) or
three (E) independent experiments. **P < 0.01, *P < 0.05 by post hoc ANOVA.
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DNA (approximately 300 bp). In the first set, we aimed to isolate all
soluble proteins (~1,300) and their associated DNA fragments by
capturing them on nitrocellulose membranes. These samples are
hereafter referred to as “Total”. In the second set of experiments,
we isolated Ab and its associated DNA fragments by immunoprecip-
itation. For both samples, the majority (Ab ~86%, Total ~90%) of
protein-associated fragments were from repetitive DNA regions, in
particular Short INterspersed Elements (SINEs) (including Alu
repeats, 63 and 49%, respectively) and from regions containing
simple repeats (11 and 33%, Fig 4B, GEO GSE99127).
We next tried to identify common sequence motifs in these data
sets. We found a pyrimidine-rich motif (Motif 1, M1, Figs 4C and
EV5A) in the “Total” DNA data set that was similar to motifs found
in both the RNA and the DNA samples associated with renatured
and immunoprecipitated Ab (Fig EV5B).
Complementary strands are required for efficient
protein renaturation
We tested the M1 motif in a 4-repeat form, i.e. M1 × 4, and a
control oligonucleotide, Motif 2, M2, randomly generated to have a
similar proportion of G/C (Fig EV5A), for their capacity to renature
the aggregated proteins.
As single-stranded (ss) DNA sequences, none of the oligonu-
cleotides supported overall renaturation (Fig 5A). However, when
both the forward and the reverse (For/Rev) oligonucleotides were
used together they efficiently supported renaturation in a concentra-
tion-dependent manner (Figs 5A and EV5C), with a theoretical stoi-
chiometry of ~1:1 (based on the assumption that the average
molecular weight of a protein is 50 kDa). The M1 × 4 oligonu-
cleotide was twice as potent in renaturing the proteins than the M2
control, indicating a sequence preference but not a strict sequence
requirement. Similar results were observed for Actin, HTT, TDP-43
and RPL7 (Fig 5B). Nucleolin (NCL), however, was equally rena-
tured by all configurations (Fig 5B). Thus, although the majority of
the tested proteins in our mixture have a preference for complemen-
tary oligonucleotides, individual differences do exist.
Both single- and double-stranded regions are needed for
efficient protein renaturation
We next investigated how the size of the DNA oligonucleotides
affects their renaturation capacity by decreasing the number of motif
repeats. We found that only oligonucleotides with at least three
motif repeats (e.g. Mx3) could efficiently renature the proteins
(Fig 5C), indicating that there could be a size requirement.
However, experiments on single-stranded segments formed after our
standard nucleic acid heat denaturation and rapid cooling step (see





Figure 4. Features of solubilising nucleic acids.
A Genomic attributes of RNA associated with renatured NF-H, Tau or Ab. Inset shows which fractions of the peaks that derive from exons or introns have their origin in
coding or non-coding transcripts, respectively.
B Characterisation of DNA associated with soluble, renatured Ab or all proteins (Total), captured either by immunoprecipitation (Ab) or absorption to membranes
(Total).
C Sequence logo of the computationally identified motif (M1) in the solubilising genomic DNA of the Total samples.
ª 2020 The Authors EMBO reports e49585 | 2020 5 of 17
Johan Aarum et al EMBO reports
To test this possibility, we performed a pre-annealing step in the
presence of 100 mM NaCl, which promotes the normal double-
stranded form. Only oligonucleotides prepared without NaCl (non-
annealed) were able to renature the proteins (Fig 5D). The amount
of NaCl used in the pre-annealing reaction had no effect on protein
solubility.
Efficient nucleic acid-mediated protein renaturation requires
looped, pyrimidine-rich single-stranded regions
Since the M1 oligonucleotide is pyrimidine-rich, we next tested
whether there is a preference for pyrimidines in the ss region by
examining the renaturing efficiency of oligonucleotides where the ss
regions were either composed of 28 consecutive pyrimidines or puri-
nes (Fig 6A). When assessed for their renaturing capacity, oligonu-
cleotides with a ss region of pyrimidines were superior to the same
oligonucleotides containing a ss region of purines (Fig 6B).
We then examined a series of oligonucleotides, all containing
similar double (ds) and single-stranded regions but positioned at dif-
ferent locations along the DNA (see second panel of Fig 6C for their
theoretical structures). Of these, the most efficient configuration
was the ds/ss/ds forms, in particular the 3x-loop or 3x-bulge
oligonucleotides (Fig 6C).
Synthetic DNA oligonucleotides can replicate the effect of
endogenous RNA in cell lysates
We next examined whether these oligonucleotides could prevent
protein aggregation caused by enzymatic RNA degradation in cell
lysates. Both single-stranded and, in particular, complementary
DNA oligonucleotides almost completely prevented protein aggrega-
tion following RNase A/T1 treatment (Figs 6D and EV5D).
The unexpected finding that the single-stranded oligonucleotides
were also capable of preventing protein aggregation, albeit less than
complementary DNA oligonucleotides (Fig 6D), indicates that they
may complement with endogenous RNA in the lysate, forming struc-
tural RNA/DNA hybrids. However, RNase H treatment of the lysate
had little or no effect (Fig EV5D), suggesting that any hybrids
present are protected.
Renaturation of protein aggregates from Amyotrophic Lateral
Sclerosis patient brain
Finally, we isolated aggregated proteins from brain tissue samples
of two patients with ALS and investigated whether NF-H within
these proteins could be renatured (after denaturation with GuHCl)
using nucleic acids. We examined neurofilament (NF) as it is
found in protein aggregates of several neurodegenerative diseases
(reviewed in Didonna & Opal, 2019), including ALS (Mendonça
et al, 2005) and was readily detected by Western blot in the
A B
C D
Figure 5. Renaturing characteristics of selected motifs.
A Proportion of aggregated proteins after renaturation with either
single-stranded (Forward or Reverse) or complementary strands (For/Rev)
of the selected M1x4 or the control oligonucleotide, M2x4.
B Western blot analysis of proteins renatured with either single-stranded or
double-stranded M1x4 or M2x4 DNA oligonucleotides.
C The effect on protein re-aggregation from varying the number of DNA motif
repeats when complementary oligonucleotides are given together.
D Protein aggregation after renaturation with the M1x4 DNA oligonucleotides
pre-annealed with 100 mM NaCl or vehicle (None).
Data information: Data are expressed as a fraction of vehicle (Ve) and
represent the mean  s.d of three to four independent experiments.
**P < 0.01, *P < 0.05 by post hoc ANOVA.
▸Figure 6. Structural characteristics of protein-solubilising oligonucleotides and renaturation of ALS brain-derived protein aggregates.A Cartoons of ds/ss/ds oligonucleotides having either pyrimidines (T or C) or purines (A) in the ss region.
B Proportion of protein aggregation following renaturing with the ds/ss/ds oligonucleotides shown in (A).
C Renaturing capacity of structurally different oligonucleotides. The diagrams on the right show a theoretical structure of each oligonucleotide. All oligonucleotides,
except the 3x-loop and 3x-bulges, contain a stretch of 30 Ts in the single-stranded regions and the same sequences (15 nucleotides each) in the double-stranded
regions. The 3x-loops and 3x-bulges oligonucleotides have 3 stretches of 9 Ts and the same sequence in the ds-regions.
D Proportion of protein aggregation in Jurkat cell lysate supplemented with various amounts and configurations of the M1x4 or M2x4 DNA oligonucleotides.
E Insoluble proteins from two ALS brain tissues were chemically denatured in guanidine hydrochloride and treated with either buffer (Vehicle), total RNA from Jurkat
cells or the complementary strands of the M1x4 DNA oligonucleotides (M1 F/R) (Pellet 1, top panel). After removal of GuHCl, the soluble fraction from these samples
was treated with RNase and any aggregated proteins (Pellet 2) analysed by Western blot (middle panel). Remaining supernatants were then treated with Benzonase
to degrade any remaining nucleic acids and aggregated proteins collected by centrifugation and analysed by Western blot (bottom panel). Proteins aggregated by
enzymatic RNA degradation in Jurkat cell lysates, which do not contain NF-H, were used as a control.
Data information: Data in (B and C) are expressed as a fraction of vehicle (Ve), while data in (D) are expressed as the amount of aggregation observed without any
oligonucleotides present (A/T1). All bars represent the mean  s.d of two to four independent experiments. **P < 0.01 by post hoc ANOVA.
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starting brain lysates while we could not detect TDP-43 in the
same, possibly due to low amount. Total RNA and the M1x4
oligonucleotides efficiently renatured NF-H from the ALS samples,
while samples treated with vehicle show pronounced re-aggrega-
tion (Fig 6E, top and second panel). No NF-H signal was observed
in the Jurkat cell samples (used as control) as these cells do not
express NFs. These were instead positive for Actin (Fig 6E).
Ribonuclease treatment of the soluble fractions (Sup 1) of proteins
renatured with RNA caused re-aggregation of NF-H and Actin, but
had no effect on the proteins renatured with the M1x4 DNA
oligonucleotides, which remained soluble even after 16 hour at
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DNA-containing fractions were efficiently re-aggregated after a
further treatment step with the non-selective nuclease, Benzonase
(Fig 6E, lower panel).
Discussion
Many proteins are known to bind RNA, for example the well-charac-
terised hnRNP family of proteins involved in RNA splicing (Swan-
son & Dreyfuss, 1988). In our study, we build on previous findings
that solubility of several RNA-binding proteins can be enhanced by
RNA (Shelkovnikova et al, 2014; Sun et al, 2014; Burke et al, 2015;
Kovachev et al, 2017, 2019; Maharana et al, 2018; Mann et al,
2019). We provide novel insights into how a wide range of proteins,
many of which are not known to bind to RNA, are maintained in a
soluble state in vitro. We show that this heterogeneous set of
proteins is prevented from aggregation by association with RNA
and, crucially, that the presence of intact RNA is required to main-
tain them in a soluble state in cell and tissue lysates (Figs 1–3). We
also provide evidence that RNA is required for the functionality of
some proteins, as exemplified by the pronounced difference in ATP-
hydrolysing activity between proteins renatured in the presence or
absence of RNA (Figs 3E and EV4C). Finally, we provide a tantalis-
ing link between these observations and human disease by demon-
strating the efficient renaturation of insoluble proteins isolated from
human ALS brain tissue.
Enzymatic RNA degradation causes the aggregation of a consis-
tent set of proteins from neuronal cell lysates. Although there is a
significant over-representation of RNA-binding proteins amongst
them (394 of 1,312 proteins), the vast majority lack conventional
RNA-binding domains. This raises at least two possible explanations
for the variety of aggregated proteins. First, either most of the
proteins associate with RNA through non-conventional RNA-binding
regions or, alternatively, the degradation of RNA initiates the aggre-
gation of a few RNA-associated proteins (i.e. seed proteins) which
then sequester a large number of other proteins, irrespective of their
association with RNA. While a combination of these two scenarios
is likely, and both are supported by the literature (Olzscha et al,
2011; Castello et al, 2012), our data favour the first possibility as
the major driving force of protein aggregation mediated by enzy-
matic RNA degradation. This is because in vitro renaturing of the
proteins in the presence of the correct nucleic acids efficiently main-
tains solubility of the vast majority of them after removal of guani-
dine hydrochloride (Figs 3, 5 and 6). Should, however, a small set
of RNA-binding seed proteins cause the aggregation of the majority,
only these would be expected to require RNA for renaturation, while
most of the other proteins should be unaffected (if the RNA-binding
seed proteins are not also efficient chaperones).
Fundamentally, and based on the generalisation that the average
molecular weight of a protein is 50 kDa, we find that in order to
achieve efficient refolding, the nucleic acids and the proteins need
to be present in equimolar quantities [i.e. 30 lg of proteins
(~600 pmol) is efficiently renatured by 600 pmol of oligonu-
cleotides, see e.g. Fig 5]. Such a stoichiometry suggests that each
protein needs to be associated with one oligonucleotide to maintain
solubility. These figures are in line with what has been observed for
other aggregate-prone proteins such as the prion protein and FUS
(Maharana et al, 2018; Kovachev et al, 2019). If seed-driven co-
precipitation was a major force, a much lower oligo-to-protein ratio
would be expected, as only the few seed proteins need to be associ-
ated with the nucleic acid.
The cellular proteome contains many polyanion-binding proteins
which are critical for proper function of cells and organisms (re-
viewed in ref. Jones et al, 2004). With respect to protein stability
and aggregation, the effect of polyanions varies, sometimes in
opposing ways, for different proteins, or even between different
polyanions on the same protein. As an example of these varying
and conflicting effects, aggregation and pathological conversion of
the prion protein is stimulated by the presence of RNA and possibly
by endogenous proteoglycans, but is inhibited by heparin and
exogenous forms of proteoglycans (Caughey & Raymond, 1993;
Wong et al, 2001; Deleault et al, 2003; Vieira et al, 2014). Similarly,
FUS aggregation is either inhibited or promoted by the presence of
presumably different species of RNA (Shelkovnikova et al, 2014;
Lin et al, 2015). Tau aggregation on the other hand has been
reported to be stimulated by RNA (Kampers et al, 1996; Zhang et al,
2017), while the aggregation of Ab has been reported to be inhibited
(Mathura et al, 2005; Takahashi et al, 2009), a finding also con-
firmed here. Thus, it is clear that polyanions, at least in vitro, have
diverse and sometimes paradoxical effects on protein structure and
solubility, possibly depending on the protein/polyanion concentra-
tion (Kovachev et al, 2017, 2019; Maharana et al, 2018).
Consistent with these findings and those in the accompanying
paper (Begeman et al, 2020), our data show a varying capability of
different nucleic acids to promote protein renaturation and maintain
solubility and, strikingly, this effect is not directly determined by
sequence, but primarily by structure (Figs 5 and 6). This agrees with
recent findings that highly structured RNAs have more interactions
with proteins than RNAs with low structural complexity (Sanchez de
Groot et al, 2019). In our study, the most efficient renaturing and
aggregate-preventing nucleic acids consist of pyrimidine-rich loops
or bulges interspersed by stretches of double-stranded regions, e.g.
nucleic acids with a ds/ss/ds configuration (Figs 6B and C). In addi-
tion, the M1 oligonucleotide prevents protein aggregation when both
strands are provided, while the same amount (in moles) of ss
oligonucleotides (i.e. twice the amount of the ds oligo) fails to do so
(Figs 5A and B). Similarly, when the two strands are pre-annealed,
i.e. seemingly forming a perfect ds strand, the renaturing effect is all
but lost (Fig 5D). These results also suggest that the anionic charge
provided by the nucleic acids (mainly by the phosphate backbone)
cannot be its sole contribution, as the same amount of charge is
provided by the two different configurations. This notion is further
supported by the much higher efficiency observed for oligonu-
cleotides with a high proportion of pyrimidines in the single-stranded
region as compared to their purine-rich counterparts (Fig 6). Indeed,
the preference for pyrimidines over purines suggests that the bases
themselves, and not solely the negative sugar backbone per se, are
important for the solubilising effect. Such structural dominance may
also explain some of the conflicting effects observed with polyanions
on protein solubility(Shelkovnikova et al, 2014; Lin et al, 2015).
More generally, and as also suggested by others (Zhang et al, 2015),
such disparate effects point to the intriguing possibility that some
nucleic acids may not only prevent protein aggregation but may
actually promote/induce the same.
The structure- and base-dependent principles summarised above
explain the majority of the observed effects, but we do see
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deviations from these rules for individual proteins. For example,
while nucleolin clearly requires nucleic acids for efficient renatu-
ration, similarly efficient renaturation is achieved with either
single-stranded or looped oligonucleotides (Fig 5B). Thus, it is
likely that other structures, besides the highly efficient looped/
bulge configuration described here, can efficiently renature indi-
vidual or groups of proteins. Indeed, sequences forming G-Quad-
ruplex structures efficiently prevent and enhance protein folding,
including in living E. coli cells (Begeman et al, 2020). Similarly,
bacterial 23S ribosomal RNA and nucleic acid homopolymers (e.g.
single-stranded poly Ts) have recently been shown to assist renat-
uration/refolding of a number of proteins, an effect suggested to
derive from the nucleic acids functioning as non-protein molecular
chaperones (Chattopadhyay et al, 1996; Sulijoadikusumo et al,
2001; Docter et al, 2016). Although our data support the general
conclusions of these studies, we suggest that the solubilising
nucleic acids are integral parts of these complexes with roles
beyond traditional chaperones, whose effects are usually energy-
dependent and mediated through transient interactions of impor-
tance mainly for initial folding. This view is backed by our finding
that ATP-hydrolysing proteins require the continuous presence of
RNA for activity in vitro and, similarly, enzymatic degradation of
RNA from proteins renatured in the presence of RNA causes them
to re-aggregate. Of note, all our renaturing experiments were
performed in the absence of traditional energy sources such as
ATP.
The main feature in solubilising genomic DNA is interspersed
repeat elements, in particular SINE elements and low-complexity
regions. This is true both for individual aggregation-prone proteins
(Ab) as well as for the majority of the proteins, i.e. Total (Fig 4B).
While some of these may represent true associations, it is plausible
that we are observing a pure in vitro effect. The argument for this is
that similar, but divergent, repeats are likely to readily form the
ds-ss-ds structures found here to be highly efficient in protein
renaturation.
What is the nature of the protein–RNA associations? Following
on from our arguments above, our data support a form of interac-
tion where the permissive nucleic acid (RNA) is an integral but non-
covalent part of certain proteins or protein complexes. To be biolog-
ically relevant, these arrangements are likely to be dynamic, with
proteins and RNA being changeable, i.e. the same RNA may associ-
ate with different proteins and vice versa. Indeed, such interchange-
ability is supported by our in vitro sequencing and oligonucleotide
characterisation studies as individual proteins are found associated
with different nucleic acids, and different proteins are found associ-
ated with the same nucleic acids (Fig 4). Similar promiscuity is
likely to exist also in cells (Maharana et al, 2018), as it is unlikely
that the solubility of a particular protein is maintained only by any
one particular RNA.
The protein–RNA associations are influenced by nucleic acid struc-
ture, as discussed above, but are also likely to be determined by post-
translational modifications of the proteins. Indeed, the capacity of
several RNA-binding proteins to undergo phase transition in vitro is
inhibited by arginine methylation, e.g. FUS (Hofweber et al, 2018;
Qamar et al, 2018) or serine phosphorylation, e.g. TDP-43 (Wang
et al, 2018). More specifically, certain arginine/serine rich proteins
(e.g. SRSF Protein Kinase 1) require either association with RNA or
serine phosphorylation to be soluble in cell lysate (Nikolakaki et al,
2008). However, in addition to such post-translational modification,
it is likely that associations with other proteins or macromolecules
could replace the requirement for RNA. In support of this observa-
tion, for some of the proteins we examine here, like HTT and RPL7,
RNA degradation causes substantial aggregation with little or no
soluble protein left in the supernatant (Figs 2A and C). For others,
e.g. NF-H, FUS and TDP-43, only a proportion appears to aggregate
with varying amounts still detected in the soluble fraction, even after
prolonged RNA degradation. This could also explain why we do not
see any visible enrichment of aggregated proteins compared with the
input when analysed on PAGE gels (Figs 1B and EV1A). However,
the amount of proteins, both in terms of mass and numbers,
combined with the poor resolution of PAGE gels makes direct
comparisons of different bands problematic.
It is clear that RNA has several important biological roles besides
its conventional function as a template for translation and assisting
in protein synthesis. These include acting as post-transcriptional
regulators (e.g. miRNA), as structural scaffolds (e.g. ncRNA and
rRNA), as cofactors (primers for DNA replication) and as enzymatic
entities, i.e. ribozymes. The data presented here suggest that RNA
has an additional role in maintaining proteins in cell and tissue
lysate in a soluble and presumably functional form.
Finally, our data indicate that alterations to RNA could contri-
bute to pathological protein aggregation, providing a mechanistic
rationale for the observed aggregation of the same proteins across
multiple diseases.
Materials and Methods
Cells and ALS samples
Neurons were differentiated from human neural stem cells (hNP1
cells) by withdrawal of basic FGF for 6 days, as described (Jones
et al, 2011). The majority (> 95%) of the cells differentiate into
Map2- and b III-tubulin-positive cells within 6 days (Jones et al,
2011).
Jurkat T cells and HEK 293T (CRL-3216, ATCC) were maintained
in RPMI 1640 (21875-034, Life Technologies) supplemented with
10% FCS (Life Technologies) and 1 x Penicillin-Streptomycin
(15070063, Life Technologies). All cells were maintained at 37°C in
5% CO2.
Cortices from day 16-21 C56BL mice were dissected at room temper-
ature (RT), rolled on filter paper to remove most of the meninges and
immediately frozen on dry ice and stored at 80°C until use.
The ALS brain samples were obtained from The Netherlands
Brain Bank (NBB), Netherlands Institute for Neuroscience, Amster-
dam (open access: www.brainbank.nl), under ethical permission
2009/148. All material was collected from donors from whom a
written informed consent for a brain autopsy and the use of the
material and clinical information for research purposes had been
obtained by the NBB. Samples were obtained from the precentral
gyrus of two ALS donors, both male, 62 and 71 years of age, with
an ALS diagnosis confirmed neuropathologically by the detection of
TDP-43 inclusions, particularly in the spinal cord. The study of
proteins from human ALS tissue has been granted to AM by the
London—City & East Research Ethics Committee, reference number:
09/H0703/27.
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Enzymes and reagents
RNase T1 (AM2280), RNase V1 (AM2275), RNase A/T1 cocktail
(EN0551), DNase I (2222) and Yeast tRNA (15401-011) were from
Thermo Fisher Scientific. RNase A (R4642), Sodium acetate (S7899)
and EtOH were from Sigma. RNase 1f (M0243) was from New
England Biolabs (NEB). Heparin (07980) was from Stemcell Tech-
nologies. Guanidine hydrochloride (BP178-1) was from Fisher
Scientific.
Preparation of cell-free lysates from neurons and mouse cortex
Differentiated neural stem cells were detached by trypsin (0.5%,
Life Technologies) and collected in RPMI 1640 medium with 10%
FCS (Life Technologies). Cells were pelleted by centrifugation and
washed twice in ice-cold PBS (14190-094) before being lysed in four
cell-pellet volumes of either Lysis Buffer 1 [20 mM Tris–HCl pH 7.5,
150 mM NaCl, 3 mM EDTA, 1% Triton X-100, 0.5% Na-Deoxycho-
late, 1X protease inhibitors cocktail (Roche), 1 mM DTT] or Lysis
Buffer 2 [20 mM Tris–HCl pH 7.5, 150 mM NaCl, 1.5 mM MgCl2,
1% Triton X-100, 0.5% Na-Deoxycholate, 1X EDTA-free protease
inhibitors cocktail (Roche), 1 mM DTT]. Most experiments were
performed in Lysis Buffer 1, except when DNase I or RNase V1 treat-
ment was performed (Fig 1D), in which case Lysis Buffer 2 was
used. Lysed cells were sonicated (Bioruptor, Diagenode) at maxi-
mum setting for 5 s on ice and centrifuged at 21,000 g for 30 min at
4°C. The supernatant was filtered through a 0.1 lm syringe filter
(Santa Cruz, sc-358809) into new tubes and the protein concentra-
tion determined with the BCA kit (Thermo Fisher) according to the
manufacturer’s instructions. Lysates were diluted in Lysis Buffer-1
or Lysis buffer-2 to 2–4 lg/ll, and treated as described below.
Mouse cortical tissue was thawed on ice and disrupted in cold
PBS using a 1-ml pipette tip. Disrupted tissue was washed 3 times in
PBS before being lysed in Lysis Buffer 1 and prepared as described
above for human neurons.
Ribonuclease treatment and isolation of aggregated proteins
Typically, 150–400 lg cell lysates at 2–4 lg/ll were mixed with
indicated amounts of ribonucleases, DNase I or Vehicle (50% Glyc-
erol in 20 mM Tris–HCl pH 7.5) and incubated at 37°C for one hour,
shaking at 1,200 rpm for 5 s every two minutes. Samples were then
centrifuged at 21,000 g for 15 min at +4°C and the supernatants
removed and saved for analysis. The pellets were washed twice in
500 ll RIPA buffer (50 mM Tris–HCl pH 8.0, 150 mM NaCl, 0.5%
Na-deoxycholate, 0.1% SDS, 1% Triton X-100) at RT and dissolved
in 20 mM Tris–HCl pH 7.5, 2% SDS, 8M Urea, by sonication
(Bioruptor, Diagenode) at maximum setting for 5 min at RT.
Samples for SDS–PAGE analysis were mixed with 4X LDS Loading
Buffer (Life Technologies) supplemented with DTT (Sigma) to 100
mM final concentration and heated for 10 min at 70°C before being
loaded on SDS–PAGE gels (Life Technologies).
Video recording of RNase-treated cell lysate
Jurkat T-cell lysate at 10 mg/ml, prepared as described above, was
divided into two quartz cuvettes at RT with or without 5 ll RNase
A/T1 or Vehicle and mixed. Recording was done with a Canon
digital camera and started immediately (time 0) taking 60 frames/
second for a total of 30 min.
Immobilisation of RNase A
100 lg RNase A at 1 lg/ll was coupled to Tosyl activated magnetic
beads (Life Technologies) for 20 h at 37°C according to the manufac-
turer’s instructions. After quenching and washing, the coupled RNase
A was re-suspended in 0.1% BSA in PBS and kept at +4°C until use.
Approximately 50% activity remained after coupling, as determined
on yeast tRNA using the RiboGreen kit (Life Technologies).
Inhibition of RNase A and addition of pre-hydrolysed RNA
RNase A inhibition: 200 lg lysate was mixed with 0.1 ll RNase A
(~3 mg/ml) and increasing concentrations of RNasin (Promega), as
indicated. Hydrolysis of RNA: 40 lg of total RNA in TE buffer
(10 mM Tris–HCl pH 8.0, 1 mM EDTA) was incubated with 10 ll
immobilised RNase A for 1 h at 37°C. RNase A was removed by
magnetic separation and the hydrolysed RNA mixed with 120 U
RNasin and kept on ice until used. Alternatively, 40 lg total RNA in
0.1 M NaOH was incubated at 85°C for 1 h and then adjusted to pH
7.5 with 1 M Tris–HCl pH 7.0. RNase A digested and NaOH hydrol-
ysed RNA was then added to 200 lg of neuronal lysate, prepared as
outlined above, and incubated at 37°C for 1 h. Aggregated and
soluble proteins were collected as before and analysed by SDS–
PAGE.
Cloning and use of TDP-43 and Ab
All PCRs were performed with Q5 polymerase (NEB) according to
the manufacturer’s instructions. Human Ab 1-40 was PCR-amplified
from full length APP (Origen, #RC209575) using Abeta_XhoI_F and
Abeta_BamHI_R primers (Table EV1), purified and then cleaved
with Xho I and Bam HI (both NEB). After further purification, the
fragments were ligated into the Xho I and Bam HI sites of pEGFP-N3
(Clontech), creating Ab fused in frame to the N-terminus of GFP.
HEK293T cells, plated at a density of 0.2 × 106 cells/well in a 24-
well plate, were transfected with Ab-GFP or empty vector using
FuGENE HD (Promega). For each well, we used 0.6 lg DNA and
2 ll FuGENE HD in a total volume of 30 ll OptiMEM (Life Tech-
nologies). Cells were harvested 48 hours after transfection and
washed in PBS and then either stored at 80°C or used directly.
Thawed or fresh cells were lysed in 80 ll Lysis Buffer 1 as described
above and treated with RNase A/T1 for one hour at 37°C. Aggre-
gated proteins were collected by centrifugation and samples
processed and analysed by SDS–PAGE as described above.
Human TDP-43 was PCR-amplified with TARDBP BspHI and
TARDBP Not I primers (Table EV1) from cDNA, prepared from
Jurkat RNA using Superscript II (Thermo Fisher Scientific) accord-
ing to the manufacturer’s instructions. Purified product was cleaved
with Nco I and Not I and cloned into pA4D5-8mRFP (Markiv et al,
2011), creating TDP-43 with a C-terminal His tag. Ligated plasmids
were transformed into BL21 (DE3) cells (C2527, NEB) and correct
clones verified by Sanger sequencing. A single colony was grown
overnight at 37°C in Luria-Bertani Broth (LB) in the presence of
2.5% glucose and ampicillin (50 lg/ml). We found that the pres-
ence of glucose, which further suppresses the T7 promoter in
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pA4D5-8mRFP, was critical to allow the expression of TDP-43. The
overnight culture was diluted 20 times in fresh LB medium with
glucose (2.5%) and ampicillin (50 lg/ml) and grown at 37°C until
an OD600 of approximately 0.8. The bacteria were then pelleted by
centrifugation and re-suspended in fresh LB supplemented with 1
mM IPTG (GEN-S-02122-5, Generon) to induce expression, and left
shaking at 250 rpm at RT for 2 hours. Recombinant TDP-43 was
purified using the Ni-NTA Spin Column purification kit (31014,
Qiagen), essentially according to the manufacturer’s instructions.
Briefly, bacteria were lysed in Buffer 1 (6 M GuHCl, 0.1 M Na Phos-
phate, 10 mM Tris–HCl pH 8.0) by sonication and insoluble debris
cleared by centrifugation (21,000 g, 30 min). Spin column-captured
proteins were washed twice in Buffer 1 adjusted to pH 6.3 and thrice
in Buffer 1 adjusted to pH 4.5 and then eluted in 6 M GuHCl, pH
2.0. Purity was determined by separating a TCA-precipitated (to
remove GuHCl) sample on an SDS–PAGE gel followed by analysis
on a Bioanalyzer Protein-230 chip and was judged to be more than
80% (Appendix Fig S1). 5 lg recombinant TDP-43 was used for
renaturation, in the presence or absence of various amounts of total
Jurkat RNA, using the procedure for “renaturation through dialysis”
described below. To quench released Ni2+ in the protein samples
before renaturation, EDTA was added to a final concentration of 10
mM before the addition of DTT (see procedure below).
Nucleic acid-mediated renaturation by dialysis
Proteins were isolated from neuronal or Jurkat cell lysate by RNase
A/T1 treatment and centrifugation. Pelleted proteins were dissolved
in 50 ll of denaturation buffer (20 mM Tris–HCl pH 7.5, 6 M Guani-
dine hydrochloride, 1% Triton X-100, 20 mM DTT) and sonicated
for 5 min at RT. The protein concentration was determined with the
BCA kit (Thermo Fisher) and diluted to 0.4 lg/ll in denaturation
buffer. 30–100 lg of solubilised proteins was mixed with 0.5X, in
lg, of RNA, DNA or heparin (all in TE buffer). All nucleic acids
were heat-denatured at 96°C for 3 min and then rapidly cooled on
ice before addition to the denatured proteins. The nucleic acid/
protein mixture was transferred to dialysis tubes (see below)
equipped with a 6–8.000 kDa cut-off membrane (Spectrum Lab).
Dialysis was performed against 600 ml PBS buffer at 4°C overnight,
after which the PBS was replaced with fresh PBS (400 ml) and the
container placed in a water bath and kept at 37°C for 1 h. The dial-
ysed samples were transferred to 1.5-ml tubes and the volume
adjusted to 100-200 ll with PBS. 7.5–10% of this was taken as
Input. Aggregated proteins (Pel 1) were pelleted by centrifugation at
21,000 g for 10 min at +4°C, washed twice in RIPA buffer and
processed for SDS–PAGE as before. 7.5–10% of the supernatant was
saved (Sup 1) and the remaining supernatant was either divided
into two new tubes supplemented with 0.5 ll vehicle or 0.5 ll
RNase A/T1 or the whole sample placed in one tube and treated
with 0.5 ll RNase A/T1. All samples were incubated at 37°C for one
hour and centrifuged as before. Pelleted proteins (Pel 2) were
washed as before and dissolved in SDS/Urea and sonicated. Equal
volumes of each fraction were separated on SDS–PAGE gels and
then either stained with coomassie or transferred to membranes for
Western blot analysis.
Dialysis tubes were prepared by drilling a 3-mm hole in the lid of
a 1.5-ml microcentrifuge tube (Crystal Clear, StarLab). The tube was
then cut 1 cm from the top and a new intact lid inserted at the
bottom. After sample addition, the tube was sealed with a dialysis
membrane and capped with the drilled lid. This creates a dialysis
tube where one end is in contact with the surrounding solution,
separated by the membrane. Tubes were placed in the dialysis solu-
tion with the holed side facing down.
Nucleic acid-mediated renaturation through two-step dilution
Proteins aggregated by enzymatic RNA degradation were isolated
and denatured in denaturation buffer (20 mM Tris–HCl pH 7.5, 6 M
Guanidine hydrochloride, 1% Triton X-100, 20 mM DTT) as
described above. The protein concentration was determined with
the BCA kit (Thermo Fisher) and diluted to 5.55 lg/ll in denatura-
tion buffer. Typically, 30 lg of denatured proteins, on ice, was
mixed (by vortexing) with indicated amounts of nucleic acids,
prepared in 1 X TE buffer, to achieve a 1:10 dilution, e.g. 5 ll of
denatured proteins + 45 ll of diluted nucleic acids. All nucleic acids
were heat-denatured (96°C, 3 min) and cooled on ice before use,
except when pre-annealed oligonucleotides were used. Pre-annealed
oligonucleotides were prepared in TE buffer supplemented with
100 mM NaCl and placed in a PCR machine at 96°C for 3 min
followed by cooling to RT for approximately 45 min. All protein/
nucleic acid mixtures were incubated for 5 min on ice and then
diluted 10× with cold Renaturing buffer (10 mM Tris–HCl pH 7.4,
30 mM NaCl), e.g. 50 ll original mixture + 450 ll of Renaturing
buffer. After incubation for 10 min on ice, samples were placed at
37°C for 1 h, shaking at 1,200 rpm for 3 s every second minute.
Aggregated and soluble proteins were separated by centrifugation,
21,000 g for 30 min. Aggregated proteins were solubilised in 20 mM
Tris–HCl pH 7.5, 2% SDS, 8M Urea by sonication (Bioruptor,
Diagenode) at maximum setting for 5 min at RT and either used for
SDS–PAGE or the amount of protein determined using the BCA
assay. When determining the amount of protein, the whole pellet
was used in a typical 225 ll reaction, e.g. 25 ll sample + 200 ll
BCA reagent. In the figures, the amount of aggregation is usually
expressed as a percentage of the amount of aggregation observed in
the vehicle control, i.e. in samples treated with TE buffer only.
SDS–PAGE and Western blot analysis
Heated samples were separated on 4–12% Bis-Tris gels (Life Tech-
nologies) in MOPS or MES buffer and either transferred to 0.2 lm
nitrocellulose or 0.45 lm PVDF membranes (both GE Healthcare)
for 2 h at 45V on ice or, alternatively, used directly for coomassie
staining (ProtoBlue, National Diagnostics) according to the manu-
facturer’s protocol. In figures with Input and Supernatants, these
represent 10%, typically 30 lg of protein, while for the Pellets the
full amount was loaded. After transfer, membranes for Western blot
were blocked for one hour at RT in 5% milk in TBS-T (50 mM Tris–
HCl pH 7.5, 150 mM NaCl, 0.05% Tween-20) and incubated with
primary antibodies in the same solution or TBS-T/5% BSA over-
night at +4°C. Membranes were then washed 4 × 5 min in TBS-T
and incubated for 1 h at RT with HRP-conjugated secondary anti-
bodies diluted in 5% milk/TBS-T. Membranes were then washed as
before and incubated for 5 min in ECL Prime (GE Healthcare) before
being exposed to films (Thermo Fisher). Primary antibodies used
were: TDP-43 (NEB, #G400), HTT (NEB, #D7F7), FUS (Santa Cruz,
#sc-47711), MAPT (NEB, #Tau46), NF-H (mouse, Covance, #SMI-
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32R), NF-H (rabbit, Sigma, # N4142), Ab 6E10 (Covance, #SIG-
39320), ACTB (Sigma, #A2228), RPL7 (Abcam, #ab72550), PABP
(Abcam, #ab21060), GFP (Abcam, #ab1218), HNRNPA1 (Protein-
Tech, #11176-1-AP) and HNRNPD (ProteinTech, #12770-1-AP). All
primary antibodies were used at 1:1,000 dilution, except ACTB
(1:4,000), NF-H (1:4,000), GFP (1:2,000), FUS (1:100) and RPL7
(1:2,000). As secondary antibodies, we used Donkey anti-Rabbit
HRP (#NA934V) or Sheep anti-Mouse HRP (#NXA931), both from
GE Healthcare, diluted 1:50,000 in 5% milk-TBS-T.
Isolation and renaturation of brain protein aggregates
Brain tissues (~200 mg frozen) were homogenised for approximately
30 s in 2 ml 0.8 M NaCl, 1% Triton X-100, 0.1 M EDTA, 0.01 M Tris–
HCl pH 7.4, 1 mM DTT using a TissueRuptor (Qiagen). The homoge-
nate was then centrifuged for 5 min at 2,500 g at 4°C and the super-
natant transferred to a new tube on ice followed by further
homogenisation using a 27-G needle and syringe. The samples were
then centrifuged at 21,000 g at 4°C for 30 min and the supernatant
collected. SDS and Na-deoxycholate were added to the supernatant to
0.1 and 0.5% final concentrations, respectively, and incubated for
10 min at RT. 500 ll of each sample was overlaid on 800 ll of
sucrose cushion (1 M sucrose, 0.8 M NaCl, 1% TX-100, 0.5% Na-
deoxycholate, 0.2% SDS, 50 mM Tris–HCl pH 7.8) and centrifuged at
167,000 g for 2 h at 4°C. The supernatants were decanted and
discarded and the pellet re-suspended in PBS supplemented with NaCl
to 500 mM and transferred to new tubes. Pellets were washed twice
in PBS/0.5 M NaCl by centrifugation at 21,000 g for 30 min and then
dissolved in 6 M GuHCl, 1% Triton X-100 and 20 mM Tris–HCl by
sonication. Brain and Jurkat samples were diluted to 2 lg/ll, and
30 lg used for renaturation through dilution as described above, using
total Jurkat RNA or the DNA versions of the M1 × 4 oligonucleotides
(Table EV1). Renatured samples were incubated for 1 hour at 37°C,
shaking at 1,200 rpm every 5th second. Aggregated proteins (Pellet 1)
were collected by centrifugation (21,000 g, 1 h, 4°C) and saved for
analysis. The supernatants were supplemented with RNase A/T1 and
incubated with shaking at 1,200 rpm at 37°C overnight. Aggregated
proteins (Pellet 2) were collected by centrifugation as above and the
supernatant supplemented with MgCl2, 1 mM final concentration, and
Benzonase (sc-391121B, Santa Cruz) and incubated at 37°C for 1 h,
shaking as above. Aggregated proteins (Pellet 3) were collected as
above. All pellets (1–3) were dissolved in 2% SDS/8M Urea by sonica-
tion and analysed by Western blot as described.
ATP-binding and hydrolysis
100 lg proteins aggregated by enzymatic degradation of RNA in
human neuronal or Jurkat cell lysates were renatured with 50 lg of
total RNA or Ve (TE buffer) as described above. After dialysis, the
samples were adjusted to 250 ll with PBS and centrifuged at
2,000 g for 15 min, to remove protein aggregates that would later
co-sediment with the agarose beads. Capturing of ATP-binding
proteins was performed on 75 ll of this mixture using 30 ll of
Aminophenyl-ATP- or naked-agarose beads (Jena Bioscience)
according to the manufacturer’s protocol. Elution was performed by
two sequential 10-min incubations in 20 ll 1X LDS loading buffer
(Life Technologies) supplemented with DTT (100 mM final concen-
tration). One fourth of the eluted samples was separated on 4–12%
NuPage gels (Life Technologies) and the gels stained with
coomassie blue (ProtoBlue, National Diagnostics). The remaining
eluate from two independent replicates was electrophoresed approx-
imately 1 cm into a 4–12% NuPage gel and the top piece of the gel
excised and prepared for mass spectrometry analysis as described
below. To measure ATP hydrolysis, we used the ADP-GloTM Kinase
Assay (Promega) according to the manufacturer’s instructions.
Briefly, 5 ll of renatured proteins were mixed in a white 96-well plate
(Santa Cruz Biotechnology) with ATP (100 lM final concentration)
and 0.1 ll RNase A/T1 mixture or vehicle (50% Glycerol in 20 mM
Tris–HCl pH 7.5), all diluted in 1X PBS, 5 mM MgCl2, 2 mM DTT, in
a total volume of 15 ll and incubated at RT for 1.5 h. Non-hydro-
lysed ATP was removed by the addition of 15 ll of ADP-Glo reagent
followed by incubation for 1 h at RT. ADP was converted back to
ATP by the addition of 30 ll Kinase Detection Reagent and the emit-
ted light quantified after 1.5 h incubation at RT using a Victor 2
Multilabel plate-reader (Wallac). All samples were run in duplicate
and data presented as the mean of three independent replicates.
RNA and DNA isolation and analysis
RNA and DNA were isolated from cells or cell lysates with TRIzol
LS or Isol-RNA Lysis Reagent (Life Technologies and 5 PRIME,
respectively), according to the manufacturer’s instructions. All RNA
and DNA samples was dissolved in either 0.1X (for RNA fragmenta-
tion, see below) or 1X TE buffer. RNA was analysed by 1.5%
agarose gel electrophoresis and visualised with ethidium bromide.
Mass spectrometry analysis
30 lg of aggregated proteins in 1 × LDS loading buffer (Life Tech-
nologies) supplemented with 100 mM DTT were separated on 4–
12% Bis-Tris gels in MOPS running buffer. After coomassie staining,
each gel lane was divided into 10 equal gel slices and cut into 1mm
cubes. Gel bands were destained and reduced with 5 mM TCEP
(Pierce) and alkylated with 50 mM chloroacetamide (Sigma) and
then digested with trypsin (Promega) for 16 hours. Samples were
desalted using homemade C18 columns and then analysed using a
Q Exactive Mass Spectrometer (Thermo) at the Central Proteomics
Facility (University of Oxford, UK). Data were analysed using
Mascot (Matrix Science) with searches performed against the
UniProt Human database. Proteins with a Mascot score greater than
or equal to 60 and with two unique peptide sequences were consid-
ered to be confidently identified. Keratin hits derived from hair (cu-
ticular) were removed from the list of ATP-precipitated proteins as
they likely represent contamination introduced during handling.
Computational analysis of proteins aggregated by enzymatic
RNA degradation
Proteins common to both LC-MS/MS samples were compiled into a
list and used for further analysis. Gene ontology analysis was
performed with PANTHER (Mi et al, 2018) using the proteome of
differentiated neural stem cells (Song et al, 2019) as reference. The
proteins with a relative abundance of more than nine in the refer-
ence set (Song et al, 2019) were used as background to re-analyse
the set of RNase-aggregated proteins using the same tool
(PANTHER). Low-complexity regions of 30 or more consecutive
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amino acids were identified with SEG (Wootton & Federhen, 1993)
using the following parameters: [30 amino acid length][3.2 low-
complexity trigger][3.55 high extension complexity]. Unstructured
regions were identified with DisEMBL (Linding et al, 2003) using the
default settings with the following changes: amino acid window of
30, join 2 and threshold 1.75. For statistical evaluation, the results
were compared with those obtained by permutation analyses. 1,000
permutations per analysis were performed. The permutations
consisted of random sets of proteins (n = 1,603), drawn from the
complete set of human proteins (http://www.uniprot.org/download
s, accessed on 07/2013) and analysed using SEG and DisEMBL with
the same settings as above. The cumulative distributions of the
proportion of low-complexity and unstructured regions were
compared with the results obtained from the proteins aggregated by
enzymatic degradation of RNA. Statistical analysis for each data set
was done using the two-sample Kolmogorov–Smirnov test (Conover,
1999) and corrected for multiple testing using Bonferroni correction.
Nucleic acid immunoprecipitation and sequencing
RNA and DNA fragmentation
Nucleic acids were isolated as described above. Total RNA (~400 lg),
prepared in 0.1X TE buffer, at 0.5 lg/ll, were chemically fragmented
in 50 mM Tris-acetate pH 8.1, 100 mM CH3CO2K and 30 mM Mg
(CH3COO)2 by incubating the samples at 96°C for 12 min. The reac-
tion was stopped by transferring the samples to ice and the addition of
0.5 M EDTA to final concentration of 45 mM. Fragmented RNA
samples were then mixed with 1/10 volume of Na-acetate (3M, pH 5,
Sigma) and 2.5 volumes of EtOH and incubated for 1 h at 80°C.
Precipitated RNA was collected by centrifugation: 30 min at 12,000 g
at +4°C and washed once in 75% EtOH before being air-dried and
dissolved in TE. Recovered RNA was spectrophotometrically quanti-
fied (NanoDrop, Thermo Fisher Scientific) and kept on ice until used.
The average size of fragmented RNA was estimated from an aliquot
analysed on a Bioanalyzer chip (RNA9000, Agilent Technologies),
according to the manufacturer’s instructions. Approximately 70% of
the initial amount of RNA was recovered after fragmentation.
Genomic DNA, in TE buffer at 3 lg/ll, was fragmented by
several rounds of sonication (Bioruptor, Diagenode) at RT until an
average fragment length of approximately 200 bp was achieved.
Nucleic acid-mediated renaturation
Proteins aggregated by enzymatic degradation of RNA in human
neuronal lysates were renatured with fragmented RNA or DNA
using the dialysis procedure described above. To achieve efficient
renaturation, the amount of fragmented RNA had to be increased
from the normal 0.5 times to 1.5 times the amount of protein
(weight/weight). After dialysis, samples were transferred to 1.5-ml
tubes and incubated at 37°C for 1 h, shaking at 1,200 rpm for 3 s
every 1.5 min. Aggregated and soluble proteins were separated by
centrifugation (21,000 g, 30 min, +4°C). The soluble fraction was
collected and divided into several tubes for immunoprecipitation or
capturing onto nitrocellulose membranes, see below.
Native RNA Immunoprecipitation
Human neuronal cell lysates were prepared as described above
under “Preparation of cell free lysates from neurons and mouse
cortex”. 200 lg of lysate was incubated with 3 lg anti-NF-H (N4142,
Sigma), 3 lg anti-Ab (4G8, SIG-39220, Covance) or 3 lg mouse IgG
(Sigma) and incubated rotating for 2 h at +4°C. Antibodies were
captured by the addition of 15 ll Protein A magnetic beads (10002D,
Thermo Fisher Scientific) pre-blocked in 5% BSA, 30 lg M1 × 4 R
oligo in PBS/0.1% Triton X-100 for 1 h at RT and incubated for
30 min at RT. Magnetic beads were collected using a magnet and
washed twice in PBS, 0.5% Triton X-100, twice in PBS, 500 mM
NaCl, 0.5% Triton X-100, and once in PBS, 1,000 mM NaCl, 0.5%
Triton X-100 and once in TE. RNA was isolated with the GeneJET
PCR Purification Kit according to the manufacturer’s instructions
with the following alterations: RNA was eluted from the magnetic
beads by the addition of 50 ll 6 M guanidine hydrochloride. The
supernatants were collected and mixed with 100 ll Binding Buffer,
100 ll water and 300 ll 2-propanol and loaded onto the column. Co-
purified DNA was removed by on-column digestion, using the
RNase-Free DNase Set (Qiagen) reagents and protocol. Eluted RNA
was then precipitated with Na-Acetate and EtOH, using glycogen
(R0561, Thermo Fisher Scientific) as a carrier. DNase-treated
samples were dissolved in 10 ll water and used for library prepara-
tion using the NEBNext Ultra II Directional RNA Library Prep Kit and
Indexing primers (E7760 and E7335, respectively, both NEB) accord-
ing to the manufacturer’s instructions. Libraries were pooled and
paired-end sequenced (2 × 75 bp) on the NextSeq 500 platform (Illu-
mina). Two biological replicates of each immunoprecipitation were
analysed, except for 4G8 where only one sample was analysed. Data
can be accessed at GEO GSE99127.
RNA Immunoprecipitation of renatured proteins
RNA-renatured proteins (~40 lg) were supplemented with 1 lg
anti-NF-H (N4142, Sigma), 1 lg anti-Tau (T9450, Sigma), 1 lg
anti-Ab (4G8, SIG-39220, Covance) or 1 lg anti GFP (11122,
Thermo Fisher Scientific) and incubated while rotating for 2 h at
+4°C. Antibodies were captured and washed as described above.
Samples were eluted with 20 ll 6 M guanidine thiocyanate at RT
and RNA-purified from the eluate with Isol (5-PRIME), according to
the manufacturer’s instructions using 1 lg glycogen (R0561,
Thermo Fisher Scientific) as co-precipitant. RNA was dissolved in
30 lg 1× DNAs I buffer and treated with 1 ll DNAase I (2222,
Thermo Fisher Scientific) for 30 min at 37°C. The sample volumes
were adjusted to 100 ll with TE and extracted with an equal
volume of phenol (77617, Sigma) and precipitated with Na-Acetate
and EtOH, using glycogen as a carrier. DNase-treated samples were
dissolved in 10 ll water and used for sequencing library prepara-
tion using the NEBNext Directional Ultra RNA kit and Indexing
primers (E7530 and E7335, respectively, both NEB) according to
the manufacturer’s instructions, except that no initial RNA frag-
mentation was performed. Libraries were pooled and paired-end
sequenced (2 × 75 bp) on the MiSeq platform (Illumina). Two
biological replicates of each immuprecipitation were analysed. Data
can be accessed at GEO GSE99127.
DNA-immunopreciptation and membrane capture of
renatured proteins
DNA-renatured samples were prepared as described above and
aliquoted for immunoprecipitation or membrane capture. For
membrane capture, approximately 40 lg renatured proteins or frag-
mented DNA alone (20 lg, negative control) were slowly passed
through a 0.2 lm nitrocellulose membrane (1060004, GE
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Healthcare) pre-blocked with 250 lg Yeast tRNA (Thermo Fisher
Scientific). The membranes were then washed three times with
10 mM Tris–HCl pH 7.5, 100 mM KCl, 0.1% Triton X-100; twice
with 10 mM Tris–HCl pH 7.5, 500 mM KCl, 0.1% Triton X-100; and
once with 1X TE. Captured proteins and nucleic acids were eluted
by the addition of 2% SDS/8M Urea and the nucleic acids extracted
with Isol (5-PRIME) as described above. Immunoprecipitation with
Ab 4G8 (1 lg) and mouse IgG (1 lg) were performed as described
for RNA immunoprecipitation of renatured proteins above using
approximately 40 lg of renatured proteins per IP. Protein A
magnetic beads were pre-blocked for 1 h at RT with 70 lg Yeast
tRNA (Thermo Fisher Scientific). Sequencing libraries were
prepared using the NEBNext DNA ultra kit (E7370, NEB), using
NEBNext Indexing primers (E7335, NEB), and the libraries pooled
and sequenced on the MiSeq system (Illumina) using paired-end
reads of 300 bp. Data can be accessed at GEO GSE99127.
Computational nucleic acid sequence analysis
Reads from both the DNA and RNA-seq experiments were
trimmed using Trim Galore with default settings for paired-end
reads. RNA reads were aligned to the human reference genome
(hg19), using STAR (Dobin et al, 2013) using default settings.
Potential PCR artefacts in the aligned RNA-seq files were removed
by the MarkDuplicates tool in Picard-tools, using default settings.
DNA sequences were aligned to the unmasked human reference
genome (hg19) using Bowtie2. To identify enriched regions, we
employed MACS (Zhang et al, 2008), using the GFP (RNA), IgG
(Native RNA-IP and DNA-IP) or DNA-only (membrane) samples
as negative controls. We used the reads from both biological repli-
cates as input files, except for the Native RNA-IP sample of 4G8,
where only one sample passed the quality check. MACS were run
with the following settings: band width = 150 for RNA or 188 for
DNA, Broad region calling = off (RNA), Searching for subpeak
summits = on (RNA) and call-summit = on for DNA. The anno-
tatePeaks package in the HOMER software package (Heinz et al,
2010), run with default settings, was used to annotate the peak
files generated by MACS. For motif discovery, we extracted a
300 nt fragment, centred at the peak detected by MACS. We used
the MEME suite of programs (MEME-Chip, (Machanick & Bailey,
2011)) with the following settings: -meme-mod anr -meme-minw 5
-meme-maxw 50 -meme-nmotifs 6 -dreme-e 0.05 -centrimo-local -
centrimo-score 5.0 -centrimo-ethresh 10.0. Motif similarities were
evaluated with Tomtom (in the MEME suite) using default
settings.
Quantification and statistical analysis
Statistical analyses in Figs 3B and E, and 5A, C, D and 6B–D, and
EV4C and EV5D were performed by one-way ANOVA followed by post
hoc analysis with Bonferroni correction for multiple testing using the
online tool at: http://astatsa.com/OneWay_Anova_with_TukeyHSD/.
Statistical analysis for Figs. EV2D and E was performed using the two-
sample Kolmogorov–Smirnov test (Conover, 1999) and corrected for
multiple testing using Bonferroni correction. When mentioned, the
term “independent samples” refers to biological repeats of the same
experiments but using different starting material, e.g. cell lysate.
Oligonucleotides
All oligonucleotides investigated in this study were purchased from
IDT in a desalted form and used without any further purification.
Sequences of oligonucleotides are listed in Table EV1.
Data availability
The DNA and RNA immunoprecipitation data from this publication
have been deposited in the Gene Expression Omnibus (GEO) data-
base and assigned the identifier GSE99127 (https://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE99127).
Expanded View for this article is available online.
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